Cellebrite DI Ltd
NASDAQ:CLBT

Watchlist Manager
Cellebrite DI Ltd Logo
Cellebrite DI Ltd
NASDAQ:CLBT
Watchlist
Price: 20.18 USD 6.21% Market Closed
Market Cap: 4.1B USD
Have any thoughts about
Cellebrite DI Ltd?
Write Note

Intrinsic Value

The intrinsic value of one CLBT stock under the Base Case scenario is 9.52 USD. Compared to the current market price of 20.18 USD, Cellebrite DI Ltd is Overvalued by 53%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

CLBT Intrinsic Value
9.52 USD
Overvaluation 53%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Cellebrite DI Ltd

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for CLBT cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about CLBT?
Bearish
Neutral
Bullish
Discover Undervalued Stocks
Technology Industry

Fundamental Analysis

Economic Moat
Cellebrite DI Ltd

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Cellebrite DI Ltd

Provide an overview of the primary business activities
of Cellebrite DI Ltd.

What unique competitive advantages
does Cellebrite DI Ltd hold over its rivals?

What risks and challenges
does Cellebrite DI Ltd face in the near future?

Summarize the latest earnings call
of Cellebrite DI Ltd.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Cellebrite DI Ltd.

Provide P/S
for Cellebrite DI Ltd.

Provide P/E
for Cellebrite DI Ltd.

Provide P/OCF
for Cellebrite DI Ltd.

Provide P/FCFE
for Cellebrite DI Ltd.

Provide P/B
for Cellebrite DI Ltd.

Provide EV/S
for Cellebrite DI Ltd.

Provide EV/GP
for Cellebrite DI Ltd.

Provide EV/EBITDA
for Cellebrite DI Ltd.

Provide EV/EBIT
for Cellebrite DI Ltd.

Provide EV/OCF
for Cellebrite DI Ltd.

Provide EV/FCFF
for Cellebrite DI Ltd.

Provide EV/IC
for Cellebrite DI Ltd.

Show me price targets
for Cellebrite DI Ltd made by professional analysts.

What are the Revenue projections
for Cellebrite DI Ltd?

How accurate were the past Revenue estimates
for Cellebrite DI Ltd?

What are the Net Income projections
for Cellebrite DI Ltd?

How accurate were the past Net Income estimates
for Cellebrite DI Ltd?

What are the EPS projections
for Cellebrite DI Ltd?

How accurate were the past EPS estimates
for Cellebrite DI Ltd?

What are the EBIT projections
for Cellebrite DI Ltd?

How accurate were the past EBIT estimates
for Cellebrite DI Ltd?

Compare the revenue forecasts
for Cellebrite DI Ltd with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Cellebrite DI Ltd and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Cellebrite DI Ltd against its competitors.

Analyze the profit margins
(gross, operating, and net) of Cellebrite DI Ltd compared to its peers.

Compare the P/E ratios
of Cellebrite DI Ltd against its peers.

Discuss the investment returns and shareholder value creation
comparing Cellebrite DI Ltd with its peers.

Analyze the financial leverage
of Cellebrite DI Ltd compared to its main competitors.

Show all profitability ratios
for Cellebrite DI Ltd.

Provide ROE
for Cellebrite DI Ltd.

Provide ROA
for Cellebrite DI Ltd.

Provide ROIC
for Cellebrite DI Ltd.

Provide ROCE
for Cellebrite DI Ltd.

Provide Gross Margin
for Cellebrite DI Ltd.

Provide Operating Margin
for Cellebrite DI Ltd.

Provide Net Margin
for Cellebrite DI Ltd.

Provide FCF Margin
for Cellebrite DI Ltd.

Show all solvency ratios
for Cellebrite DI Ltd.

Provide D/E Ratio
for Cellebrite DI Ltd.

Provide D/A Ratio
for Cellebrite DI Ltd.

Provide Interest Coverage Ratio
for Cellebrite DI Ltd.

Provide Altman Z-Score Ratio
for Cellebrite DI Ltd.

Provide Quick Ratio
for Cellebrite DI Ltd.

Provide Current Ratio
for Cellebrite DI Ltd.

Provide Cash Ratio
for Cellebrite DI Ltd.

What is the historical Revenue growth
over the last 5 years for Cellebrite DI Ltd?

What is the historical Net Income growth
over the last 5 years for Cellebrite DI Ltd?

What is the current Free Cash Flow
of Cellebrite DI Ltd?

Discuss the annual earnings per share (EPS)
trend over the past five years for Cellebrite DI Ltd.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Cellebrite DI Ltd

Current Assets 501.5m
Cash & Short-Term Investments 279.7m
Receivables 100.3m
Other Current Assets 121.4m
Non-Current Assets 127.8m
Long-Term Investments 42.8m
PP&E 28m
Intangibles 40m
Other Non-Current Assets 16.9m
Current Liabilities 272.9m
Accounts Payable 61.8m
Accrued Liabilities 4.5m
Other Current Liabilities 206.7m
Non-Current Liabilities 58m
Other Non-Current Liabilities 58m
Efficiency

Earnings Waterfall
Cellebrite DI Ltd

Revenue
385.2m USD
Cost of Revenue
-59.9m USD
Gross Profit
325.3m USD
Operating Expenses
-269.1m USD
Operating Income
56.2m USD
Other Expenses
-373.1m USD
Net Income
-316.9m USD

Free Cash Flow Analysis
Cellebrite DI Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

Cellebrite achieved remarkable growth in Q3 2024, surpassing $100 million in quarterly revenue for the first time, reflecting a 27% year-over-year increase. Subscription revenue constituted 87% of the total. Their Annual Recurring Revenue (ARR) reached $371 million, up 26% annually. The company is optimistic, raising its full-year revenue guidance to $397-$401 million and adjusting EBITDA expectations to $96-$100 million. With Q3 gross margins at 86.1% and adjusted EBITDA margins rising to 29%, Cellebrite remains confident in its strong operational momentum and market position, targeting further growth in 2025.

What is Earnings Call?
Fundamental Scores

CLBT Profitability Score
Profitability Due Diligence

Cellebrite DI Ltd's profitability score is 63/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROE
Positive Gross Profit
Positive Free Cash Flow
Positive 3-Years Revenue Growth
63/100
Profitability
Score

Cellebrite DI Ltd's profitability score is 63/100. The higher the profitability score, the more profitable the company is.

CLBT Solvency Score
Solvency Due Diligence

Cellebrite DI Ltd's solvency score is 71/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Low D/E
Long-Term Solvency
Short-Term Solvency
71/100
Solvency
Score

Cellebrite DI Ltd's solvency score is 71/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

CLBT Price Targets Summary
Cellebrite DI Ltd

Wall Street analysts forecast CLBT stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CLBT is 22.88 USD with a low forecast of 21.21 USD and a high forecast of 25.2 USD.

Lowest
Price Target
21.21 USD
5% Upside
Average
Price Target
22.88 USD
13% Upside
Highest
Price Target
25.2 USD
25% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for CLBT?

Click here to dive deeper.

Dividends

Cellebrite DI Ltd
does not pay dividends
Shareholder Yield

Current shareholder yield for CLBT is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

Cellebrite DI Ltd Logo
Cellebrite DI Ltd

Country

Israel

Industry

Technology

Market Cap

4.4B USD

Dividend Yield

0%

Description

Cellebrite DI Ltd. engages in the provision of digital intelligence solutions for the law enforcement, government, and enterprise market. The firm is committed to providing a Digital Intelligence (DI) platform for managing DI in legally sanctioned investigations. The Platform enables users to collect, view, analyse and manage digital data throughout the entire investigation cycle. The firm's platform improves the investigation process for public defenders, police departments, state departments, armed services, legal and corporate security; this leads to an accelerated speed of investigations and increased crime clearance rates.

Contact

Petah Tikva
94 Shlomo Shmelzer Rd., P.O.B 3925
+972733948000.0
www.cellebrite.com

IPO

-

Employees

2

Officers

Founder, CEO & Director
Mr. Yossi Carmil
Chief Financial Officer
Ms. Dana Gerner
Chief Products & Technologies Officer
Mr. Ronnen Armon
Chief Strategy Officer
Mr. Leeor Ben-Peretz
Executive Chairman
Mr. Thomas E. Hogan
Vice President of Investor Relations
Andrew Kramer
Show More
General Counsel & Chief Compliance Officer
Ms. Ayala Berler Shapira
Chief Marketing Officer
Mr. David Nicholas Gee
Chief People Officer
Ms. Zohar Tadmor-Eilat
Global Chief Revenue Officer
Mr. Marcus Jewell
Show Less

See Also

Discover More
What is the Intrinsic Value of one CLBT stock?

The intrinsic value of one CLBT stock under the Base Case scenario is 9.52 USD.

Is CLBT stock undervalued or overvalued?

Compared to the current market price of 20.18 USD, Cellebrite DI Ltd is Overvalued by 53%.

Back to Top